AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has experienced a significant decline in stock value, plummeting 15 percent over the past six months. This downturn follows alarming reports of a growing investigation by Chinese regulators into alleged illegal drug imports, data breaches, and possible health insurance fraud, raising serious concerns about the company’s future in a vital market. AstraZeneca faces challenges
In response to these developments, law firm Hagens Berman has launched an investigation, urging investors affected by these issues to come forward and submit their claims. The investigation specifically targets investors in AstraZeneca’s American Depositary Shares, with the relevant class period set from February 23, 2022, to December 17, 2024. Interested parties can find further details on how to participate through the firm’s website.
Investigation into AstraZeneca’s Chinese operations
The investigation has focused on allegations that AstraZeneca employees improperly imported cancer medications, including Enhertu and Imjudo, from Hong Kong to mainland China. Compounding these allegations is a broader investigation into significant health insurance fraud. These issues have compounded investor fears regarding potential impacts on the company’s regional sales and overall financial performance.
The arrest of Leon Wang, AstraZeneca’s Executive Vice President and President for International and China operations, has intensified the situation. Following internal forecasts predicting a decline in sales within the Chinese market, investor anxiety surged, leading to the filing of legal actions in the U.S. District Court for the Central District of California.
The class action lawsuit alleges that AstraZeneca misled investors by issuing “false and misleading statements” about its exposure to legal and regulatory risks in China. It also claims that the company failed to disclose the probability of these issues significantly harming its operations.
Concerns about investor confidence first emerged in late October when AstraZeneca announced Mr. Wang’s cooperation with the investigation. This revelation caused a 3 percent drop in stock price, which worsened after reports implicated multiple AstraZeneca executives in compliance issues, leading to an additional 7 percent decline.
In light of these unfolding events, Hagens Berman continues its investigation into AstraZeneca.
Reed Kathrein, an attorney leading the investigation, stated, “Should the allegations be confirmed, it suggests AstraZeneca misled investors about the true extent of its exposure in China, a failure with potentially serious consequences.”
Whistleblowers may also explore opportunities to assist the investigation and potentially benefit from the SEC Whistleblower program, which offers rewards up to 30 percent of successful recoveries.
Source: Globe Newswire AstraZeneca faces challenges
